MarsBars/E+ through Getty Images
- FibroGen (NASDAQ:FGEN) mentioned late Friday that its chief monetary officer and chief medical officer will each be leaving the company due to funds cuts.
- The company mentioned CFO Juan Graham will stick with the company till Dec. 15, whereas CMO Dr. Deyaa Adib will leave on Nov. 1. Both had been knowledgeable of their terminations on Aug. 30, in accordance to an SEC submitting.
- FibroGen (FGEN) introduced in late July that it was slashing its U.S. workforce by 75% due to disappointing medical outcomes for its pancreatic most cancers drug candidate pamrevlumab.
- Shares of FibroGen (FGEN) closed 8% decrease on Friday.
Source: Seekingalpha